We showed that a GSK3β inhibitor selectively inhibited FHIT-deficient lung cancer by inhibiting the ATR/BRCA1/RAD51 signaling axis and BRCA1/RAD51 transcription, leading to the inhibition of HRR and genotoxic cell death. The gene discussed is GSK3B; the disease is lung cancer.